Atrial fibrillation, bleeding, and coronary intervention: current recommendationsFarhan, Serdar; Mehran, RoxanaCoronary Artery Disease: December 2017 - Volume 28 - Issue 8 - p 702–709 doi: 10.1097/MCA.0000000000000549 Review in depth Buy Abstract Author InformationAuthors Article MetricsMetrics The patient population with the need for oral anticoagulation to reduce stroke risk associated with atrial fibrillation (AF) and dual antiplatelet therapy to prevent stent thrombosis and myocardial infarction after percutaneous coronary intervention is increasing. However, patients treated with a triple therapy consisting of oral anticoagulation, aspirin, and a P2Y12 inhibitor have been demonstrated to be at high bleeding risk. The best combination of these agents and the duration of the different therapies are still uncertain. Recently, data on the safety of combinations including nonvitamin K antagonists have been published and evidence for the feasibility of a dual therapy is increasing. This review aims to provide insights to the pathophysiology of thrombus formation in AF versus coronary artery disease, summarize available data on postprocedural treatment strategies, and report current guidelines for AF patients after percutaneous coronary intervention. Furthermore, the role of stent type selection and tools to evaluate as well as strategies to reduce the individual bleeding risk will be discussed. Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute, New York City, New York, USA Correspondence to Roxana Mehran, MD, Interventional Cardiovascular Research and Clinical Trials, Icahn School of Medicine at Mount Sinai, The Zena and Michael A. Wiener Cardiovascular Institute, One Gustave L. Levy Place, Box 1030 New York, NY 10029-6574, USA Tel: +1 212 659 9641; fax: +1 646 537 8547; e-mail: email@example.com Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.